



TABLE OF CONTENTS

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF TABLES

LIST OF ABBREVIATIONS

CHAPTER 1. INTRODUCTION.....	1-10
1.1 Introduction.....	2
1.2 Aims and Objectives.....	6
1.3 References.....	8
CHAPTER 2. LITERATURE REVIEW.....	11-49
2.1 Lung Cancer and Chemotherapy: Current Status and Issues	12
2.2 Aerosolized Local Delivery for Direct Lung Administration:	
Liposomal Dry Powder Inhalers	14
2.3 Lung Cancer: Liposomal p53 Mediated Gene Therapy	17
2.3.1 p53 Anticancer Function	20
2.3.2 p53 Delivery Vectors	21
2.3.3 Liposomes as Gene Delivery Vectors	27
2.4 Chemosensitization	34
2.5 Drug and DNA Profile	36
2.5.1 pCB6+ ARG p53 – Tumor Suppressor Plasmid.....	36
2.5.2 pCMV-SPORT-βgal – β galactosidase Plasmid.....	37
2.5.3 Docetaxel Trihydrate	38
2.5.4 Etoposide.....	40
2.6 References.....	43
CHAPTER 3. ANALYTICAL METHOD DEVELOPMENT.....	50-59
3.1 Estimation of plasmid DNA (pDNA).....	51
3.2 Estimation of β-Galactosidase	52

3.3 Estimation of Etoposide	55
3.4 Estimation of Docetaxel Trihydrate:	56
3.5 References.....	58

CHAPTER 4. TRANSFORMATION, ISOLATION AND PURIFICATION OF PLASMID DNA..... 59-72

4.1 Transformation of plasmid DNA (pDNA).....	60
4.1.1 Preparation and Transformation of competent E.Coli using TransformAid™ Bacterial Transformation Kit (Fermentas):.....	60
4.1.2 Result and Discussion.....	62
4.2 Maintenance of Bacterial Cells Containing Plasmids	64
4.3 Plasmid Isolation and Purification	64
4.4 Plasmid Digestion	70
4.5 References.....	72

CHAPTER 5. LIGAND ATTACHED p53 LIPOPLEXES FOR TREATMENT OF NSCLC..... 73-109

5.1 Introduction	74
5.2 Development of Cationic Liposomes	75
5.2.1 Materials	75
5.2.2 Methods	75
5.2.3 Characterization.....	76
5.2.4 Result and Discussion	78
5.3 Lipoplex Development and Characterization	83
5.3.1 Material	83
5.3.2 Methods	84
5.3.3 Result and Discussion	85
5.4 Cell Uptake studies	89
5.4.1 Material	89
5.4.2 Development of 6 – Coumarin Liposomes and Lipoplexes	89

5.4.3 Qualitative Cell Uptake of 6 – Coumarin Lipoplexes prepared by TFH, EI and SCF technique	90
5.4.4 Result and Discussion	90
5.5 Transfection studies	92
5.5.1 Material	92
5.5.2 Method.....	92
5.5.3 Result and Discussion	92
5.6 Development of Ligand Attached Lipoplexes	95
5.6.1 Materials	95
5.6.2 Methods.....	95
5.6.3 Result and Discussion	96
5.7 Cytotoxicity of p53 Based Lipoplexes	99
5.7.1 Material	99
5.7.2 Method.....	99
5.7.3 Result and Discussion	100
5.8 Lyophilization of Lipoplexes	102
5.8.1 Material	102
5.8.2 Method.....	102
5.8.3 Result and Discussion	102
5.9 <i>In Vitro</i> lung deposition of developed lipoplexes by Anderson cascade impactor	104
5.9.1 Material	104
5.9.2 Method.....	104
5.9.3 Result and Discussion	104
5.10 Conclusion.....	105
5.11 References.....	107
 CHAPTER 6. p53 MEDIATED CHEMO-SENSITIZATION OF ANTICANCER DRUGS.....	
.....	110-154
6.1 Introduction	111

6.2 Development, Optimization and Characterization of Etoposide and Docetaxel Liposomes.....	112
6.2.1 Material	112
6.2.2 Method	112
6.2.3 Characterization.....	113
6.2.4 Result and Discussion	114
6.3 Development, Optimization and Characterization of Etoposide and Docetaxel Containing Lipoplexes	121
6.3.1 Size, Zeta Potential and % Drug Release of ETP and DTX Lipoplexes	121
6.3.2 Agarose gel retardation assay and DNaseI protection study	124
6.4 Cell Uptake Studies	125
6.4.1 Material	125
6.4.2 Development of 6 – Coumarin Liposomes and Lipoplexes	126
6.4.3 Qualitative and Quantitative Cell Uptake of 6 – Coumarin Liposomes and Lipoplexes.....	126
6.4.4 Result and Discussion	127
6.5 Transfection studies.....	129
6.5.1 Material	129
6.5.2 Transfection of Drug Containing Lipoplexes in A 549 and H 1299 cell line ...	130
6.5.3 Result and Discussion	130
6.6 Cytotoxicity studies.....	134
6.6.1 Material	134
6.6.2 Cytotoxicity Studies of ETP / DTX formulations along with p53 pretreatment and co-administration	134
6.6.3 Result and Discussion	136
6.7 p53 detection by flow cytometry	141
6.7.1 Material	141
6.7.2 Lipoplex mediated p53 expression in H 1299 cells	141
6.7.4 Result and Discussion	142
6.8 Annexin V FITC Assay.....	144
6.8.1 Material	144

6.8.2 Method.....	144
6.8.4 Result and Discussion	144
6.9 Lyophilization of Lipoplexes.....	150
6.10 <i>In Vitro</i> lung deposition of liposomes and lipoplexes by Anderson cascade impactor	151
6.8.1 Material	151
6.8.2 Method.....	151
6.8.4 Result and Discussion	151
6.11 Conclusion.....	152
6.11 References.....	153
 CHAPTER 7. SUMMARY AND CONCLUSION	155-170
7.1 Summary	156
7.1.1 Analytical method development.....	157
7.1.2 Plasmid Transformation, Isolation and Purification	158
7.1.3 Development of Ligand Attached p53 lipoplexes for Treatment of NSCLC	158
7.1.4 p53 Mediated Chemo-sensitization of Anticancer Drugs	160
7.2 Conclusion	167
7.3 Future Scope	168